Drugs used to treat type 2 diabetes, such as Ozempic and Mounjaro, are gaining popularity and are being prescribed to help people lose weight, but many people with type 2 diabetes in the metro are struggling to find an injection for their treatment. interests. Dr. Michael Crawford was diagnosed with type 2 diabetes four years ago, but recently discovered Mountjaro. Dr. Michael Crawford said, “It’s made an incredible difference for me. Like Crawford, Elda Hernandez says the drug Ozempic is important to her feeling like she can really live her life. It’s really important to me,” said Hernandez. On a scale of one to 100, 110.” The drug is very important to them. But lately they have had trouble finding it. “I called eight, nine, 10 different pharmacies and no one had it. And you go through all that phone work and three or five days later, you have to do that again,” Crawford said. “Can you fill me a prescription? My pharmacy didn’t have it, and then the pharmacist came back and said, “No, I need patients for myself,” Hernandez said. Hernandez said that she was gone for a month. and a half before her pharmacy received the prescription. And it’s a weekly beat they need to stay on top of. “It takes a couple of weeks for your body to get used to the drug and work,” Crawford said. And when he misses those injections, Crawford says he can experience urinary and stomach issues, including severe diarrhea. “I’ve had two shortages, one 10-day and one 17-day, and when I couldn’t get it, quality of life became the issue. You go through it, and you get the consequences,” Crawford said. What bothers them the most is why they can’t find it. “The problem is that doctors are prescribing it off-label to people who are taking it away from the diabetes community trying to manage the disease process,” Crawford said. Off label, for weight loss. Dr. Avin Potulori, with Methodist Health System, is an endocrinologist for both Crawford and Hernandez. He is on the Endocrine Society’s Clinical Guidelines Committee. Potulori said they aren’t the only ones struggling to access the needle. “Basically, we had to wait until the supply improved. Their diabetes would get worse. In the meantime, we would try to put them on other diabetes medications,” Potulori said. He said there was a similar drug shortage in 2021. , Wegovy, Food and Drug Administration weight loss acceptance. Doctors are looking for prescription options like Ozempic or Mounjaro. “Now you have the FDA, you know, these drugs are not approved for weight loss. And the drug company says these drugs are not approved for weight loss, but people are able to order them,” Pothuloori said. Now, they ‘But both the websites for Ozempic and Munjaro specifically point out that it is not FDA approved for weight loss, only for diabetes. And that’s what everyone likes Crawford and Hernandez want. “It helped me a little bit with the weight. But I’m not for the weight, I guess not at this age. I’m not for the weight. I feel it,” Hernandez said. After Potulori stopped using the prescription drug, the weight came right back, which has the same effect as a crash diet. “At the end of the day, these drugs They are not free from dangers. And sometimes for some people, they’re lifelong drugs,” Potulori said. Potulori says he can still see how the drugs will change obesity treatment in the future. But he emphasized that they’re not FDA-approved for weight loss right now. “I think similar drugs will lead to competition. You will get the same medicine. Thanks to these drugs, we will have much better treatments to prevent obesity,” Potulori said. All three will be safe for people who use the drug. Only for weight loss, if there is enough supply. But at the moment: “Finally, we hope that the manufacturer will be on demand. But in the short term, they shouldn’t really use a marker for weight loss,” Crawford said. We spoke to the makers of both drugs, a spokesperson for Novo Nordisk, maker of Ozympic, said: “All doses of Ozympic are now available nationwide at retail pharmacies for eligible patients with type 2 diabetes. However, pharmacies may experience regular delays, such as the time it takes to order the product from their local distribution center and geographic differences.” We are still waiting to hear from Eli Lilly, creator of Mounjaro. Top headlines A man with a history of mental health issues has been shot 200 times by non-lethal projectiles. Plans to open Omaha casino in 2024 Omaha City Council permanently removes Vinny Palermo from leadership positions.
Drugs used to treat type 2 diabetes, such as Ozempic and Mounjaro, are gaining popularity and are being prescribed to help people lose weight.
But here in the metro, many people with type 2 diabetes are struggling to find the right injection for their medical needs.
Dr. Michael Crawford was diagnosed with type 2 diabetes four years ago, but recently discovered Mountjaro.
“It made an incredible difference to me,” said Dr. Michael Crawford.
Like Crawford, Elda Hernandez says the drug, Ozempic, is essential for her to feel like she can truly live her life.
“It’s really important to me. On a scale of one to 100, 110,” Hernandez said.
Medicine is very important for them. Lately, though, they’ve had trouble finding him.
“I called eight, nine, 10 different pharmacies and nobody had it. And you go through all that phone work and three or five days later, you have to do it again,” Crawford said.
“Can you fill me a prescription? My pharmacy didn’t have it, and then the pharmacist came back and said, ‘No, I need it for my patients,'” Hernandez said.
Hernandez said she went a month and a half before her pharmacy received the prescription.
And that’s the weekly kick they need to stay on top of it.
“It takes a couple of weeks for your body to get used to the drug and work,” Crawford said.
And when he misses those injections, Crawford says he can experience urinary and stomach issues, including severe diarrhea.
“I’ve had two shortages, one 10-day and one 17-day, and when I couldn’t get it, quality of life became the issue. You go through it, and you get the consequences,” Crawford said.
What bothers them the most is why they can’t find it.
“The problem is that doctors are prescribing it off-label to people who are taking it away from the diabetes community trying to manage the disease process,” Crawford said.
Off label, for weight loss.
Dr. Avin Potulori with Methodist Health System is both Crawford and Hernandez’s endocrinologist.
He is on the Clinical Guidelines Committee of the Endocrine Society.
Potulori said they weren’t the only ones struggling to find the needle.
“Basically, we had to wait until the supply improved. Their diabetes would get worse. In the meantime, we would try to put them on other diabetes drugs,” Potulori said.
In the year In 2021, Wegovy, the Food and Drug Administration, approved for weight loss, said there was a shortage of the same drug.
This has led doctors to look for alternatives such as Ozempic or Mounjaro.
“Now you have the FDA saying, you know, these drugs are not approved for weight loss. And the drug company says these drugs are not approved for weight loss, but people are able to prescribe them,” Potulori said.
Now, they are very popular.
But both the Ozempic and Mounjaro websites point out that it is not FDA approved specifically for weight loss, only for diabetes.
And that’s all people like Crawford and Hernandez want.
“He helped me a little bit with the weight. But I’m not for the weight, I guess not at this age. I’m not for the weight. I feel it,” Hernandez said.
The weight typically comes back on after you stop using the Potulori prescription, which has the same effect as a crash diet.
“At the end of the day, these drugs are not without risks. And sometimes they are lifelong drugs for some people,” Potulori said.
Potulori said he can still see how the drugs could change obesity treatment in the future.
But now he stresses that they are not FDA approved for weight loss.
“I think the same drugs will lead to competition. The same drugs will get you out. Because of these drugs, we will have much better treatments for obesity,” Potulori said.
If there is enough supply, people using the drug only for weight loss will be fine with all three.
But for now:
“Ultimately, we hope that the manufacturer will be on demand. But in the short term, they should not be used off-label for weight loss,” Crawford said.
We spoke to the makers of both drugs, a spokesperson for Novo Nordisk, the maker of Ozympic, said: “All doses of Ozympic are now available nationwide at retail pharmacies for eligible patients with type 2 diabetes. However, pharmacies may experience regular delays. Time required to order the product from their local distribution center and geographic variations.
We are still waiting for Eli Lilly, the creator of Monjaro, to respond.
The main news
[ad_2]